Oct 2nd 2024
Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
July 24th 2023
Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.
July 21st 2023
Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.
July 21st 2023
The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.
July 21st 2023
The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.
July 21st 2023
The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.
July 20th 2023
Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.
July 17th 2023
Vector Laboratories announced the acquisition of Quanta BioDesign on July 17, 2023, which further expands the former’s portfolio of bioconjugation linkers and dyes, as well as its manufacturing sector, according to the press release.
July 17th 2023
Westlake’s third fund of $450 million will be used to grow early stage biotechnology companies.
July 14th 2023
German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.
July 12th 2023
The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.